IgE, anti-IgE therapy, and regulatory T cells: new paradigms in allergic inflammation
Clicks: 1
ID: 310016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #241 of 490 articles by views in Frontiers in surgery
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 490 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Allergic inflammation arises from a dysregulated immune response in which immunoglobulin E (IgE) plays a central pathogenic role. By binding to its high-affinity FcεRI on mast cells and basophils, IgE orchestrates the rapid activation and mediator release that underlies immediate hypersensitivity reactions. Compelling experimental evidence indicates that the pathogenic role of IgE extends well beyond of the mere effector cells degranulation, contributing also to shape antigen presentation, to regulate the function of dendritic cells, and to endorse an immune environment that favours type 2 inflammation. Within this complex network, regulatory T cells (Tregs) serve as a critical counterbalance, maintaining tolerance to environmental allergens and restraining excessive type 2 inflammatory responses. Individuals with allergic diseases often display quantitative and/or functional alterations within the Tregs compartment, including signs of phenotypic plasticity shifted toward pro-allergic states. These observations raise important questions about how IgE-mediated signalling pathways might directly or indirectly impair proper Tregs development or stability. In this context, anti-IgE therapies such as omalizumab have shown that, beyond reducing free IgE levels and downregulating FcεRI expression, they may also promote the expansion or restoration of Tregs, which might well contribute to the reestablishment of immune tolerance. Deciphering the interplay among IgE, Tregs, and anti-IgE agents can help to pave the way towards the development of innovative disease-modifying strategies for allergic diseases and other inflammatory immune-mediated diseases.
| Reference Key |
imported_1768911355_696f71fb01577
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Palomares, Oscar |
| Journal | Frontiers in surgery |
| Year | Year not found |
| DOI |
10.3389/falgy.2026.1759921
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.